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ABSTRACT Invading pathogen nucleic acids are recognized and bound by cytoplasmic (retinoic acid-inducible gene I [RIG-I]-
like) andmembrane-bound (Toll-like) pattern recognition receptors to activate innate immune signaling. Modified nucleotides,
when present in RNAmolecules, diminish the magnitude of these signaling responses. However, mechanisms explaining the
blunted signaling have not been elucidated. In this study, we used several independent biological assays, including inhibition of
virus replication, RIG-I:RNA binding assays, and limited trypsin digestion of RIG-I:RNA complexes, to begin to understand how
RNAs containing modified nucleotides avoid or suppress innate immune signaling. The experiments were based on amodel in-
nate immune activating RNAmolecule, the polyU/UC RNA domain of hepatitis C virus, which was transcribed in vitrowith ca-
nonical nucleotides or with one of eight modified nucleotides. The approach revealed signature assay responses associated with
individual modified nucleotides or classes of modified nucleotides. For example, while bothN-6-methyladenosine (m6A) and
pseudouridine nucleotides correlate with diminished signaling, RNA containing m6Amodifications bound RIG-I poorly, while
RNA containing pseudouridine bound RIG-I with high affinity but failed to trigger the canonical RIG-I conformational changes
associated with robust signaling. These data advance understanding of RNA-mediated innate immune signaling, with additional
relevance for applying nucleotide modifications to RNA therapeutics.
IMPORTANCE The innate immune system provides the first response to virus infections andmust distinguish between host and
pathogen nucleic acids to mount a protective immune response without activating autoimmune responses. While the presence of
nucleotide modifications in RNA is known to correlate with diminished innate immune signaling, the underlying mechanisms
have not been explored. The data reported here are important for defining mechanistic details to explain signaling suppression
by RNAs containing modified nucleotides. The results suggest that RNAs containing modified nucleotides interrupt signaling at
early steps of the RIG-I-like innate immune activation pathway and also that nucleotide modifications with similar chemical
structures can be organized into classes that suppress or evade innate immune signaling steps. These data contribute to defining
the molecular basis for innate immune signaling suppression by RNAs containing modified nucleotides. The results have impor-
tant implications for designing therapeutic RNAs that evade innate immune detection.
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The pattern recognition receptors of the innate immune systemmust distinguish the chemical patterns of “self” versus “non-self”
molecules. Three homologous helicases, retinoic acid-inducible gene
I (RIG-I), melanoma differentiation-associated protein 5 (MDA5),
and laboratory of genetics and physiology 2 (LGP2), constitute the
cytosolic RIG-I-like receptors (RLRs). Members RIG-I and MDA5
have similar domain architectures, including tandem N-terminal
caspase activation and recruitment domains (CARDs) that partici-
pate in signaling, a DExD/H-box helicase domain with RNA binding
and ATP hydrolysis activity, and a C-terminal domain (CTD). While
MDA5 detects long double-stranded RNA, the salient chemical
feature of RIG-I ligands is a 5= triphosphate (5=ppp) (1, 2) or diphos-
phate (3). Other reported RIG-I ligands include the panhandle struc-
tures of viral genomic RNA (reviewed in reference 4) and uridine-
rich sequences (5–7).
In the absence of ligand RNA, both RIG-I and MDA5 adopt an
autorepressed conformation, with subsequent activation eluci-
dated by structural studies (reviewed in reference 8). The 5=ppp of
an RNA ligand is bound by the RIG-I CTD, enabling subsequent
helicase:RNA interactions and ATP binding. This induces a RIG-I
conformational change that releases the CARDs for K63-linked
polyubiquitination (9) and binding of unanchored K63-linked
ubiquitin chains (10). This activated RIG-I conformer then en-
gages the adaptor, mitochondrial antiviral signaling protein
(MAVS), to mediate activation of transcription factors and
interferon-stimulated gene (ISG) induction. Genetic mutations of
MDA5 or RIG-I can produce autoimmune pathologies (reviewed
in reference 11). Both MDA5 and RIG-I are reported to use kinetic
discrimination or “proofreading” of self-ligands versus non-self-
ligands by ATP hydrolysis (12–16).
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Several studies support the hypothesis that the type and density
of RNA nucleotide modifications regulate the innate immune dis-
tinction between cellular and pathogen RNA. Recent reports sug-
gest that the N-7-methylation of Cap-0 (m7GpppNpNpN) is in-
sufficient to suppress RIG-I signaling activation and that the
ribose 2= O-methylation of Cap-1 (m7GpppNmpNpN) is critical
(17, 18). Indeed, Cap-1 methylation also prevents mRNA detec-
tion both by MDA5 (19) and by the interferon-induced protein
with tetratricopeptide repeats (IFIT) family of restriction factors
(20). Post-transcriptional modifications of internal RNA nucleo-
tides also impact innate immune detection. Karikó and colleagues
first reported that signaling through membrane-bound RNA-
sensing Toll-like receptors was significantly diminished in re-
sponse to RNA ligands containing modified internal nucleotides
(21). MDA5 detection of self-double-stranded RNA (self-dsRNA)
is blocked by A-to-I modification catalyzed by adenosine deami-
nase acting on RNA (ADAR1) (reviewed in reference 22). Muta-
tions in RIG-I and MDA5 are also associated with autoimmune
syndromes (11), where the receptors may be activated in the ab-
sence of viral infection, for example, by endogenous RNAs. Pre-
vious reports also suggest that the RIG-I response to RNA ligands
is damped by nucleotide modifications (6, 23). Despite the accu-
mulating evidence that nucleotide modifications of cellular RNA
can serve an immunoevasive role in preventing autoimmune ac-
tivation, the mechanism(s) of pattern recognition receptor signal-
ing suppression is undetermined.
Among the 100 known nucleotide modifications (24), sev-
eral modifications previously assumed to exist only in ribosomal
and transfer RNAs have recently been mapped across the tran-
scriptome of mammalian cell lines, yeast, and bacteria, with their
enrichment patterns providing clues to their biological function
in other RNA species. The density of base modifications observed
in cellular RNA is reportedly low; for example, experimental evi-
dence suggests an average of 3 to 5 sites of N-6-methyladenosine
(m6A) modification per mRNA and modification at a substoi-
chiometric frequency at each site (25). However, the biological
impact of a modification may be determined more by location
than by density, as suggested by the specific enrichment patterns
observed in transcriptome-wide mapping of m6A, 5-methyl-
cytidine (5mC), and pseudouridine (). Since it has been mapped
across the mammalian, yeast, plant, and bacterial transcriptomes,
the finding of m6A enrichment near the cap and stop codon of an
mRNA supports functional evidence of m6A regulating RNA sta-
bility, splicing, and translation (reviewed in reference 26). Distinct
from DNA methylation, 5mC in the human transcriptome was
enriched in untranslated regions and Argonaut binding sites of
mRNA and was also observed in noncoding RNAs (27). Pseudou-
ridine () has been mapped in the human and yeast transcrip-
tome and is dynamically regulated by environmental signals
(reviewed in reference 28). Human-designed 2= fluoro-
deoxyribonucleotides (2FdN), when introduced by in vitro tran-
scription or in chemically synthesized small interfering RNAs
(siRNAs), confer nuclease resistance and immunoevasive charac-
teristics (29, 30).
Here, we use a well-established RIG-I-activating RNA ligand,
the 106-nucleotide (nt) polyU/UC sequence derived from the 3=
untranslated region (UTR) of hepatitis C virus (5, 6), as a platform
for exploring the immunosuppressive potential of several nucleo-
tide modifications. We present evidence suggesting that m6A,
, N-1-methylpseudouridine (m), 5mC, 5-hydroxymethyl-
cytidine (5hmC), 5-methoxycytidine (5moC), and 2= fluoro-
deoxyribose modifications (2= fluoro-deoxyuridine [2FdU] and
2= fluoro-deoxycytidine [2FdC]) individually suppress RIG-I re-
sponses to the polyU/UC RNA ligand. The results of several dis-
tinct experimental approaches suggest that RNAs containing
modified nucleotides impact multiple steps early in the RIG-I sig-
naling pathway. Strikingly, limited trypsin digestion experiments
revealed that RNAs containing  or N-1-methylpseudouridine
(m) bound to RIG-I but failed to trigger conformational
changes associated with RIG-I activation. These data advance our
understanding of RNA-mediated innate immune signaling, with
further significance for applying nucleotide modifications to RNA
therapeutics (31).
RESULTS
In vitro transcription of RNA containing modified nucleotides
(RNAmod). Before performing assays to probe mechanisms of
innate immune signaling suppression by modified nucleotides
(see Fig. 2 to 4), we first performed validation experiments to
define RNA quality and functional activity in cell-based assays
(Fig. 1; see also Fig. S1 to S4), which included expanding our prior
work (6) to include five additional modified nucleotides. Modi-
fied nucleotide triphosphates were substituted for canonical nu-
cleotide triphosphates in T7-polymerase transcription reactions
(see Fig. S1B). Transcription products were routinely tested for
size and homogeneity by capillary gel electrophoresis (see
Fig. S1C). To control for dsRNA (32) in our preparations, we
adapted a dot blot method from Karikó and colleagues (33), using
a monoclonal antibody clone J2 that recognizes dsRNA longer
than 40 bp (34). The results demonstrated that the polyU/UC
RNAs used in our assays were free of detectable long dsRNA (see
Fig. S1D). RNA batches that failed to meet this criterion were
purified by high-performance liquid chromatography (HPLC),
using a protocol adapted from Karikó and colleagues (33), and
were then retested for dsRNA content.
RNAmod evasion of RIG-I-mediated IFN- induction. Puri-
fied polyU/UC RNAs containing canonical nucleotides (RNAcan)
or modified nucleotides (RNAmod) were then assayed in a panel
of cell-based assays (Fig. 1) to test for differences in innate im-
mune stimulation. A interferon beta (IFN-) promoter-driven
luciferase reporter assay was used previously to characterize RNA-
can and RNAmod signaling using polyU/UC RNA (6). Related
approaches were used here to validate current experimental con-
ditions and to provide direct functional comparisons with five
additional modified nucleotides transcribed into polyU/UC
(Fig. 1A) or mRNA (Fig. 1B). Distinct from our previous work (6)
where RIG-I was expressed from a transfected plasmid, the innate
immune signaling approaches described here reflect endogenous
cellular RIG-I activity instead of overexpressed RIG-I. Huh7 cells
were cotransfected with the IFN- reporter plasmid and a consti-
tutive luciferase expression transfection control plasmid. Cells
transfected with RNAcan or RNAmod were analyzed at 16 to 24 h
posttransfection (hpt). As shown in Fig. 1A, the polyU/UC RNA
containing canonical nucleotides (can) activated robust IFN-
promoter induction, in agreement with previous published re-
ports (5, 6, 35). RNAmod containing other modified nucleotides
(m6A,, m, 2FdU, 2FdC, 5mC, 5moC, and 5hmC) stimulated
significantly less IFN- reporter activity than RNAcan (Fig. 1A).
To determine if signal suppression would be observed using a
longer RNA with a lower percentage (10.3%) of uridine content,
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the assay was repeated with mRNA (~1,000 nt) encoding en-
hanced green fluorescent protein (EGFP) (Fig. 1B). The highest
interferon activation was observed using the uncapped mRNA
transcript that was transcribed using canonical nucleotides (5ppp/
can), consistent with 5ppp being an important RIG-I stimulatory
signal (1, 2). However, complete substitution of pseudouridine
for uridine (5ppp/) also reduced the IFN- response to the
5ppp-containing mRNA (Fig. 1B). As predicted, the 5ppp ac-
tivation signal was also diminished significantly in the inter-
feron induction assay using RNA containing a Cap-1 structure.
EGFP-expressing cells were observed by live-cell fluorescence
when the Cap-1/can-EGFP and Cap-1/-EGFP mRNAs were
transfected, while cells receiving the 5=ppp-containing mRNAs
(5ppp/can and 5ppp/) did not show detectable fluorescence
(data not shown), reflecting the known importance of the 5= cap
structure for mRNA translation. The absence of innate immune
signaling observed using RNAs containing modified nucleotides
could be explained by a complete failure of the RNAmod to enter
the cells. However, the literature suggests that RNAs containing
modified nucleotides retain function upon transfection with com-
mercial cationic lipid reagents (see, for example, references 36 and
37); moreover, the observed EGFP expression from mRNA con-
taining 10.3% pseudouridine demonstrated successful RNA
transfection. The results presented here strongly suggest that
RNAs containing modified nucleotides suppress or evade innate
immune stimulation.
To further validate our experimental system, two control ex-
periments were performed to demonstrate that the IFN- signal-
ing assays reflected specific RNA activation of the RIG-I innate

























P value P value P value
Mock .0009 mΨ .0035 5mC .0038
m6A .0127 2FdU .0143 5moC .0036


























5ppp / can Mock .0345
5ppp / can Cap1 / can .0387
5ppp / can 5ppp / Ψ .0390
FIG 1 RNAmod and RIG-I-mediated IFN- induction. (A) Huh7 cells were first transfected with luciferase reporter plasmids and then later mock transfected
or transfected with 400 ng of polyU/UC RNA containing canonical nucleotides (can) or polyU/UC RNA containing the indicated modified nucleotides. (B)
Following reporter plasmid transfection, Huh7 cells were transfected with EGFP mRNA containing a Cap-1 structure (Cap1) or 5=ppp terminus (5ppp) and
canonical (can) nucleotides or pseudouridine substitution (). (A and B) After an additional 16 to 24 h of incubation, cell lysates were analyzed for IFN--
promoter-driven firefly luciferase activity, and the data were normalized to constitutively produced Renilla luciferase values to control for transfection efficiency
and then normalized to the mock-treated control condition. Error bars represent the standard deviations of results determined among technical triplicates, with
results of a representative experiment shown. The statistical table reports the P values of results of paired two-tailed t tests comparing fold IFN responses between
(A) canonical polyU/UC RNA and indicated modified RNAs or between (B) the indicated mRNAs, from multiple independent experiments. Additional data are
provided in Fig. S1 and S2 in the supplemental material. (C) Huh7 cells were transfected with 400 ng polyU/UC RNA containing the indicated modified
nucleotides. After 16 h of incubation, cells were infected with VSV-GFP at an MOI of 3. At 6 h postinfection, GFP expression was visualized by live-cell
microscopy. Additional data are provided in Fig. S3 and S4 in the supplemental material. BF, bright field.
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2), and converting 5=ppp RNA to 5=OH terminus RNA with calf
intestinal phosphatase (CIP) prevents RIG-I CTD:RNA interac-
tion and subsequent signaling activation (1). We observed that
subjecting the polyU/UC RNAs to CIP treatment reduced Huh7
cell IFN- reporter responses (see Fig. S2A in the supplemental
material), consistent with a RIG-I-mediated response. Huh7.5
cells were used as a second control to demonstrate RIG-I-specific
receptor activation. Huh7.5 cells express RIG-I protein with a
T55I point mutation in the RIG-I CARDs, which blocks down-
stream signaling (38), including blocking the response to ligands
such as polyU/UC (39). Indeed, the Huh7.5 cells lacked IFN-
induction responses to canonical and modified polyU/UC RNA
but retained responses to long dsRNA, most likely detected by the
MDA5 receptor (see Fig. S2A). In addition, endogenous ISG ex-
pression in response to the transfected polyU/UC RNA was ob-
served using Huh7 cells but not Huh7.5 cells (see Fig. S2B and C).
Taken together, the data presented in Fig. 1 and in Fig. S1 to S3
strongly suggest (i) that RNA transcript quality was carefully con-
trolled, (ii) that the polyU/UC ligand indeed signals through the
cytoplasmic RIG-I pattern recognition receptor to activate an
IFN- reporter, as well as endogenous ISGs expression, and (iii)
that 106-nt polyU/UC RNA and 996-nt EGFP mRNA transcribed
with modified nucleotides significantly suppress RIG-I signal
transduction compared with RNAs containing canonical nucleo-
tides.
RNAmod evasion of RIG-I antiviral signaling. To verify that
the observed IFN- induction and ISG expression indeed re-
flected an antiviral state, Huh7 cells were challenged with vesicular
stomatitis virus (VSV). Briefly, Huh7 cells were first transfected
with RNA to activate RIG-I-dependent signaling. RNAcan trans-
fection was expected to activate interferon expression and there-
fore to reduce VSV replication. At 16 h posttransfection, cells were
washed and infected with recombinant VSV encoding a GFP re-
porter (VSV-GFP). Huh7 cells challenged with VSV-GFP were
analyzed at 6 h postinfection (hpi) with fluorescence microscopy
imaging (Fig. 1C). Infection was quantified by flow cytometry of
unfixed cells to detect native GFP fluorescence (see Fig. S3A in the
supplemental material). Cells receiving no polyU/UC RNA during
pretreatment were 70% to 95% GFP positive (GFP), reflecting a
permissive state for VSV replication. Cells pretreated with RNA-
can were only 1% to 5% GFP, indicating that viral replication
was suppressed. Conversely, pretreatment with RNAmod did not
protect cells from VSV-GFP infection. Similar results were ob-
served in a dengue virus (DenV) challenge, as assayed by flow
cytometry (see Fig. S3B). These results are consistent with the
luciferase reporter data (Fig. 1A) and ISG induction data (see
Fig. S2C), demonstrating that RNAcan signals through RIG-I to
induce interferon expression and an antiviral state, while RNA-
mod is unable to stimulate RIG-I-mediated antiviral signaling.
One additional control was performed before proceeding to
mechanistic studies. Differential innate immune stimulation by
modified RNA (RNAmod) could potentially be explained by dif-
ferential RNA stability. We therefore analyzed RNA stability in cell
extracts. By adding radiolabeled polyU/UC RNA to 293T cell ex-
tracts, we observed that RNA containing  (RNA) and RNA
containing m6A (RNAm6A) had a half-life similar to that of RNA
with canonical nucleotides (RNAcan), while RNA2FdU was hy-
perstable (see Fig. S4 in the supplemental material). Indeed, the
2FdU ribose modification has been previously reported to confer
nuclease resistance (29). These data suggest that reduced RIG-I
signaling responses to modified RNA are not explained simply by
differential RNAmod stabilities. Taken together, the data pre-
sented in Fig. 1 and in Fig. S1 to S4 define a robust experimental
system for use in further mechanistic studies (Fig. 2 to 4) of RNA-
can and RNAmod.
RNA:RIG-I binding affinity. The first mechanistic analysis
tested the hypothesis that RIG-I signaling correlates directly with
RNA:RIG-I binding affinity. We used a filter binding approach to
quantify 32P-radiolabeled RNAcan and RNAmod binding to in-
creasing concentrations of purified recombinant RIG-I protein.






















X –btn can m6A Ψ mΨ 2FdU 2FdC 5mC
INP
BND
29% 2% 100% 40% 99% 76% 149% 145% 161%
Kd (nM) 95% CI (nM) R2 P value
can 186 159 – 219 0.977 na
2FdU 29 21 - 39 0.947 <.0001
Ψ 255 208 - 312 0.967 .0141
m6A* >1069 755 - 1515 0.928 <.0001
FIG 2 RNAmod and RIG-I binding affinity. (A) Radiolabeled polyU/UC
RNA was incubated with purified recombinant RIG-I to allow complex for-
mation and then applied to a nitrocellulose membrane filter, which retains
RNA-protein complexes, while unbound RNA passes through the membrane.
The fraction of bound RNA was normalized to the maximum observed signal.
Combined data from at least three independent experiments per ligand are
presented with solid lines indicating the best-fit nonlinear regression and
dashed lines indicating 95% confidence intervals. (B) Calculated equilibrium
binding dissociation constants (Kd) derived from data shown in panel A, in-
cluding 95% confidence interval, goodness of fit (R2), and statistical test
(P value), demonstrating a significant difference between the two curve pa-
rameters Kd and slope for each comparison of RNAmod versus RNAcan. For
the m6A data (indicated by an asterisk [*]), the experimental maximum ob-
served signal was normalized to 100% RNA bound, although a binding plateau
was not observed. Therefore, the accurate RIG-I:RNAm6A binding constant is
likely higher (lower affinity) than that presented. Additional data are provided
in Fig. S5 in the supplemental material. (C) Biotinylated polyU/UC RNA with
the indicated modified nucleotides was added to Huh7 cell lysate. Negative
controls included biotinylated X-RNA (X) and nonbiotinylated polyU/UC
(-btn). RIG-I:RNA complexes that were captured with streptavidin-
conjugated paramagnetic beads (BND) were detected by Western blotting
with anti-RIG-I, relative to the RIG-I in 10% input (INP). The signal was
quantified in the BND fraction relative to the INP fraction and normalized to
canonical RNA (100%).
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periments, where radiolabeled RNAcan was incubated with in-
creasing concentrations of nonradiolabeled competitor RNAs (see
Fig. S5 in the supplemental material).
The equilibrium dissociation constants revealed by the filter
binding experiments strongly suggest that nucleotide modifica-
tions have differential effects on RIG-I:RNA affinities (Fig. 2A and
B). RNA2FdU bound RIG-I with the highest affinity, with an ap-
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FIG 3 RIG-I:RNA conformation as probed by limited trypsin digestion time course. (A to D) RIG-I fragments were detected by Western blotting with a
monoclonal antibody to the helicase domain. Cell extracts were incubated with trypsin in the absence (A [–RNA]) or presence of RNA ligands, including
nonbinding control yeast tRNA (B [tRNA]), polyI:C (C), or polyU/UC (D), and with 1 mM ATP or AMP-PNP. Aliquots were removed from the reaction at
various time points (minutes) post-addition of trypsin. Additional data are provided in Fig. S6 in the supplemental material. (E) Biotinylated RNAs were used
in pulldown experiments to test for RNA binding by the 80-kDa and 55-kDa RIG-I fragments. Trypsin digests ( tryp) and control lysates ( tryp) were
incubated without RNA (-RNA), with nonbiotinylated polyU/UC RNA (-btn), with biotinylated polyU/UC RNA (can), or with biotinylated X RNA (X) in the
presence of AMP-PNP. After 1.5 h, trypsin digestions were quenched by adding protease inhibitor and incubated with streptavidin paramagnetic beads. RIG-I
present in the bead-bound fraction (BND) versus the input fraction (INP) was detected by Western blotting.
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RNA had approximate dissociation constants of 186 nM and
255 nM, respectively, which were statistically significantly distinct
(Fig. 2B). Alternatively, two independently transcribed RNAm6A
preparations each bound RIG-I with much lower affinity; more-
over, the binding did not plateau, even at the highest RIG-I con-
centrations that were feasible in the experimental design. There-
fore, the maximum observed RNAm6A binding value was
calibrated to 100% in order to generate a nonlinear regression,
revealing a dissociation constant greater than 1,069 nM (Fig. 2B).
The experiments represented in Fig. 2A were performed using
bacterially expressed recombinant RIG-I protein. We comple-
mented this approach with a pulldown method that instead used
endogenously expressed RIG-I in Huh7 cell extract. PolyU/UC
RNA was transcribed with biotin-11–CTP and incubated with
Huh7 cell extract. RIG-I that coisolated with the biotinylated RNA
via paramagnetic streptavidin beads was detected by Western
blotting. Negative-control RNAcan transcribed without biotin did
not isolate RIG-I, confirming that the RIG-I signal in the bead-
bound fraction requires biotin-based RNA pulldown. As a second
control, we used biotinylated 5=ppp X-region RNA (98 nt), also
derived from the 3=UTR of hepatitis C virus (HCV) and previ-
ously observed to have lower RIG-I affinity than 5=ppp polyU/UC
RNA (5, 6). We observed a weak but detectable RIG-I interaction
with biotinylated X-RNA, as expected (Fig. 2C). PolyU/UC
RNAm6A pulled down less RIG-I than RNAcan, in agreement
with the quantitative filter binding assay. While the pseudouridine
modifications ( and m) had limited impact on RIG-I pull-
down, the 2= fluoro-deoxyribose and 5mC modifications ap-
peared to enhance RIG-I binding affinity compared to the RNA-
can results, also in agreement with the quantitative filter binding
assay.
Taken together, the results from the two independent RIG-I:
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FIG 4 RNAmod and RIG-I trypsin sensitivity. (A to D) Digestion of 293T cell lysate for 2 h in the presence of polyU/UC RNA with the indicated modifications
or canonical nucleotides (can), at increasing polyU/UC RNA concentrations (0, 12.5, 25, 50, 100, 200, 400, 800, and 1,600 nM), in the presence of 2 mM ATP or
AMP-PNP. Data represent results of Western blotting for 55-kDa and 80-kDa fragments of RIG-I with anti-helicase antibody. (E) Digestions of 293T cell lysate
performed for 1.5 h in the presence of AMP-PNP and polyU/UC RNA with the indicated modifications, at increasing concentrations (0, 33, 100, 300, and
900 nM), or mass equivalent of polyI:C.
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RNA binding assays (Fig. 2) suggest that signal transduction in-
tensity does not necessarily correlate directly with RIG-I:RNA
binding affinity (Fig. 1 and 2). These observations were unex-
pected because each of the RNAs containing the nucleotide mod-
ifications failed to activate RIG-I signaling in the IFN- reporter
assay and the antiviral signaling assay (Fig. 1). These data suggest
that mechanisms of innate immune suppression are not uniform
among nucleotide modifications, motivating additional experi-
ments to define the relevant mechanisms.
Limited trypsin digestion of RIG-I:RNA complexes. As de-
scribed previously, productive RNA:RIG-I binding and signaling
are accompanied by RIG-I conformational changes that release
the CARDs for K63-linked polyubiquitination (9) and binding of
unanchored K63-linked ubiquitin chains (10). We hypothesized
that RNAs containing certain modifications, such as pseudouri-
dine, may bind to RIG-I without triggering the protein conforma-
tional changes necessary for downstream signaling. To test this
hypothesis, we adapted a limited trypsin digestion protocol that
had been used previously to assay the conformational states of
RNA bound to recombinant RIG-I protein (35, 40–43). While
previous reports used limited tryptic digestions to assay the con-
formation of bacterially expressed recombinant RIG-I (5, 35, 41,
43, 44), we adapted the digestion method to use cell extracts with
mammal-expressed RIG-I. We performed protease experiments
by adding polyU/UC RNAs to cell lysates prepared from 293T cells
containing a chromosomally inserted construct for doxycycline-
inducible human RIG-I overexpression.
Limited trypsin digestions were performed in the presence
of ATP or of a nonhydrolyzable ATP analogue, adenylyl-
imidodiphosphate (AMP-PNP). AMP-PNP promotes RIG-I do-
main compaction (8) and stabilizes the ternary complex of RIG-
I:RNA:AMP-PNP without the ATP hydrolysis that is reported to
dissociate RNA from the helicase domain (13, 14). Briefly, RNA
and ATP or RNA and AMP-PMP were added to cell lysates and the
mixtures were incubated at room temperature to allow RIG-I:
RNA complexes to form. Next, trypsin was added to the reaction
mixture to partially digest the complexes, and the protease activity
was halted by adding SDS gel sample buffer and boiling. Tryptic
protein fragments were separated by SDS-PAGE, and RIG-I-
specific fragments were detected by immunoblotting with a com-
mercial anti-helicase domain antibody raised against RIG-I amino
acids (aa) 201 to 713.
Control experiments were performed to demonstrate signal
specificity and to define protease digestion parameters (Fig. 3A to
D), prior to testing the RNAs containing modified nucleotides
(Fig. 4). Overall, the results of the RIG-I trypsin digestions focused
our attention on 80-kDa and 55-kDa RIG-I tryptic fragments that
were differentially trypsin resistant depending on the RNA ligand
used. In the absence of exogenous RNA ligand (-RNA) and in the
presence of negative-control yeast tRNA, a relatively stable 55-
kDa RIG-I fragment was observed (Fig. 3A and B). We interpret
the 55-kDa RIG-I fragment as representing the trypsin sensitivity
of autorepressed RNA-free RIG-I conformation. This 55-kDa pat-
tern was observed in the presence of ATP or in the presence of
AMP-PNP, consistent with the assumption that ATP hydrolysis
does not regulate the autorepressed conformation of RIG-I (45).
An 80-kDa RIG-I fragment remained trypsin resistant when
either dsRNA mimic poly(I · C) (polyI:C) or polyU/UC RNA was
added to the lysates (Fig. 3C and D). We interpret the 80-kDa
fragment to represent the trypsin resistance of the RNA-bound
RIG-I in the activated conformation (8). Digestions performed
with the same RNAs in Huh7 cell lysate also generated 80-kDa and
55-kDa RIG-I fragments (see Fig. S6 in the supplemental mate-
rial), suggesting that the patterns were not an artifact of the RIG-I
construct cloned into the doxycycline-inducible 293T cell line.
Interestingly, visualizing the 80-kDa RIG-I tryptic fragment under
the polyU/UC RNA conditions required AMP-PNP, suggesting
that ATPase activity dissociates the RNA ligand and returns RIG-I
to the autorepressed conformation (Fig. 3D). We therefore hy-
pothesized that the 80-kDa fragment represented the trypsin re-
sistance of a RIG-I:RNA complex involving helicase domain in-
teractions.
To test for RNA binding activity of the RIG-I tryptic fragments,
we performed trypsin digests in the presence of biotinylated
polyU/UC RNA. While both 55-kDa and 80-kDa RIG-I fragments
were formed during the digestion (Fig. 3E [INP]), only the 80-kDa
fragment was captured with biotinylated polyU/UC RNA during
the streptavidin bead pulldown (Fig. 3E [BND]). This observation
suggests that the 80-kDa RIG-I fragment indeed represents the
trypsin resistance of a RIG-I:RNA complex.
RNAmod impact on RIG-I:RNA trypsin sensitivity. We next
applied the limited trypsin digest assay to define RIG-I confor-
mational states under conditions of binding to RNAmod. The
experimental conditions presented in Fig. 3A to D included a
constant RNA concentration and a digestion time course. To
extend this analysis, we tested trypsin sensitivity with RNAmod
using a single reaction time point with increasing RNA concen-
trations (Fig. 4). Interestingly, the digestion patterns were
similar across RNAmod ligands in assays performed in the pres-
ence of ATP; however, in the presence of AMP-PNP, we ob-
served differential results with the 80-kDa RIG-I fragment
(Fig. 4). This suggests that the RNAmod ligands differ in their
propensity to bind the helicase domain and that they coopera-
tively bind ATP or the AMP-PNP nucleotide. We further ex-
panded our analysis to test RNAs containing other nucleotide
modifications, including N-1-methylpseudouridine (m), 2=
fluoro-deoxycytidine (2=FdC), 5-methylcytidine (5mC), and
5-methoxycytidine (5moC). The data (Fig. 4E) demonstrate that
nucleotide modifications with similar chemical structures yielded
common results in stabilizing the 80-kDa RIG-I conformer. Both
RNA and RNAm failed to generate the 80-kDa fragment,
while RNA5mC and RNA5moC supported weak 80-kDa fragment
formation. Interestingly, the 2= fluoro-deoxyribose RNAs trig-
gered robust 80-kDa fragment formation with either uridine or
cytidine bases (Fig. 4E). These patterns suggest that RIG-I inter-
action with particular modified nucleotides in the polyU/UC li-
gand enables or prevents the activating protein conformational
change and thus defines a mechanism of suppression of antiviral
signaling (Fig. 5).
DISCUSSION
During a pathogen infection, innate immune activation is essen-
tial for mounting a protective response; however, the responses
must be closely regulated to prevent autoimmune effects. Several
groups have proposed that nucleotide modifications distinguish
self-RNAs from non-self-RNAs, based on observations that nucle-
otide modifications suppress Toll-like receptor 3 (TLR3), TLR7,
and TLR8 (21, 29), RIG-I (6, 23), and other components of the
innate immune system (46, 57). The goal of our study was to begin
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to define the mechanism(s) by which chemically disparate base
and ribose modifications suppress or evade RIG-I signaling.
Using a highly stimulatory RNA ligand derived from HCV
genomic RNA (5, 6), rigorous in vitro transcription RNA quality
control (see Fig. S1 in the supplemental material), and multiple
assays of RIG-I signaling (Fig. 1 to 4), we have tested and com-
pared unmodified RNA and RNAs containing one of eight nucle-
otide modifications. Overall, we found that polyU/UC RNAs
transcribed with each nucleotide modification dramatically sup-
pressed or failed to activate RIG-I antiviral signaling compared to
polyU/UC RNA transcribed with canonical nucleoside triphos-
phates (NTPs) (Fig. 1). Further work using multiple assays (Fig. 2
to 4) unexpectedly revealed that the modified nucleosides have
different effects on RIG-I binding and on the conformation of the
RIG-I:RNA complex and thus have different mechanisms of sig-
naling suppression.
The limited trypsin digest experiments provided key data that
distinguished the modified nucleotide classes. We adapted previ-
ously reported methods (35, 41, 44, 47) to probe the conforma-
tions of RIG-I:RNA complexes, electing to use mammalian cell
extracts instead of purified recombinant RIG-I. Both the 55-kDa
RIG-I fragment and the RNA-induced 80-kDa RIG-I fragment in
our extract assay were recognized by a monoclonal anti-helicase
domain antibody (Fig. 4; see also Fig. S6) but not by an anti-CARD
antibody (data not shown). The 80-kDa fragment was also cap-
tured with biotinylated-polyU/UC RNA in a streptavidin bead
pulldown, demonstrating RNA binding function (Fig. 4E). These
observations are consistent with the interpretation that the 80-
kDa fragment represents RIG-I lacking the CARDs. Meanwhile,
the 55-kDa fragment lacked RNA binding activity in the biotinyl-
ated RNA pulldown assay. Therefore, we hypothesize that the 55-
kDa fragment corresponds to the RIG-I helicase domain lacking
both the CTD and CARDs. A direct comparison of the partial
tryptic digestion patterns reported here and by others (35, 41, 44,
47) is challenging because of the use of different protein sources
(extracts versus purified recombinant protein) and different de-
tection methods (Coomassie staining versus immunoblotting)
and differences in the RNA ligands used. Nonetheless, the tryptic
digestion results, which were determined using internally consis-
tent experimental conditions and controls, provide compelling
data on RIG-I conformational changes induced by RNAs contain-
ing modified nucleotides.
Analyzed by multiple assays (Fig. 1 to 4), RNAs were observed
to affect early signal transduction events in a nucleotide
modification-specific manner (Fig. 5). RNAm6A, which bound
RIG-I with low affinity (Fig. 2), did not trigger the conversion to
the activated RIG-I conformer in the trypsin digest assay (Fig. 4B).
Adenosines comprise only 6 of the 106 polyU/UC RNA nucleo-
tides (see Fig. S1A in the supplemental material); therefore, the
per-nucleotide functional effects on RIG-I:RNAm6A binding af-
finity were dramatic. PolyU/UC RNA containing pyrimidine
modifications (, m, 5mC) bound RIG-I with affinity compa-
rable to or greater than canonical RNA (Fig. 2) while failing to
induce the AMP-PMP-stabilized conformational change(s) that
was detected as the 80-kDa fragment in the trypsin digest assay
(Fig. 4E).
RNAs containing the ribose modification (2FdU or 2FdC)
yielded unexpected and yet mechanistically informative experi-
mental results. RNA2FdU and RNA2FdC bound RIG-I with high
affinity (Fig. 2) and efficiently triggered a partial trypsin digestion
pattern that represented activated RIG-I (Fig. 4). Unexpectedly,
the RIG-I binding and RIG-I conformational changes observed
with RNA2FdN were not accompanied by antiviral signaling;
rather, IFN reporter induction was not observed (Fig. 1). One
explanation for the differential assay results is that RIG-I helicase
domain ATPase activity was able to drive helicase dissociation
from RNA2FdN to abort antiviral signaling in the cytosol, while
the AMP-PNP present in vitro in the limited trypsin digest assay
stabilized the activated RIG-I:RNA2FdN complex (Fig. 4D). Oth-
ers have proposed RIG-I ATPase negative regulation of RNA
binding as well (13–16).
The methods and observations presented here are relevant to
designing therapeutic mRNAs and siRNAs containing modified
nucleotides that enhance RNA stability and reduce immunogenic-
ity (48). The present study was limited to reporting on two RNA
ligands (106-nt polyU/UC and 996-nt EGFP mRNA), a single pat-
tern recognition receptor (RIG-I), and a panel of eight nucleoside
modifications amenable to in vitro transcription. Future work
should probe the mechanisms by which modified RNAs of diverse
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FIG 5 Model of RIG-I interaction with RNAcan and RNAmod. (Step 1) RIG-I is in an autorepressed conformation in the absence of ligand. (Step 2) 5=ppp RNA
binds the RIG-I CTD. RNAm6A binds RIG-I with lower affinity than RNAcan. (Step 3) The RIG-I helicase domain binds the RNA, triggering a protein
conformational change. RNAs containing, m, or 5mC fail to induce RIG-I conformational change. (Step 4) The released CARDs of the activated RIG-I:RNA
complex are ubiquitinated and signal downstream. This process is hypothesized to be inefficient for RIG-I:RNA2FdN, possibly due to ATPase negative regulation
of RNA binding. Ubiquitinated RIG-I induces MAVS aggregation on the surface of the mitochondria. (Step 5) Mitochondrial complexes mediate downstream
antiviral signaling. Among the RNAs tested, we observed that only RNAcan triggered RIG-I antiviral signaling.
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other innate immune receptors and effectors (MDA5, TLRs, and
IFIT-family proteins). Determination of an appropriate RNA li-
gand for chemical synthesis would enable exploration of addi-
tional RNA modifications, including locked nucleic acids, and a
phosphorothioate backbone (49, 50).
In addition to the diversity of synthetic nucleotides, over 100
naturally occurring nucleotide modifications, some of which may
have evolved roles in self-detection versus non-self-detection by
the innate immune system, have been previously described (24). It
is likely that pattern recognition receptors detect more than the
mere presence or absence of certain modifications; instead, a nu-
anced combination of the double- or single-strandedness of the
RNA, the location of the modification (proximity to the 5= or 3=
RNA terminus), and the sequence context of the modification is
likely important.
We also speculate that pathogen-derived RNA ligands may
contain modifications that influence detection by RIG-I; for ex-
ample, dengue virus encodes a methyltransferase that acts primar-
ily on the viral RNA cap and yet also catalyzes 2= O methylation of
adenosine residues in viral RNA, tRNA, and rRNAs in vitro (51).
While the ribose methylation of the viral cap is critical for evasion
of innate immune detection, the biological role of internal 2=
O-methyladenosine is unclear. Interestingly, influenza virus
(negative-sense RNA genome) and Rous sarcoma virus (RNA ret-
rovirus) produce viral transcripts with m6A modifications (52,
53), presumably catalyzed by cellular nuclear methyltransferases.
The function of modifications—such as m6A—in the stability,
translation, and immunogenicity of viral RNAs has not been ex-
plored in detail. Continued research at the interface of innate im-
munology and RNA modification biology will provide insights
into self-detection versus non-self-detection, applicable in design-
ing nucleic acid drugs to improve human health.
MATERIALS AND METHODS
Cell culture and virus stocks. Huh7 cells were from the P. Yang labora-
tory (Harvard Medical School). Huh7.5 cells were from the C. Rice labo-
ratory (Rockefeller University). 293TdoxRIG-I cells were generated from
Flp-In T-Rex HEK293T cells (Thermo Fisher) by E. Karayel (Austrian
Academy of Sciences). These cells are induced with doxycycline (Sigma-
Aldrich) (10 g/ml; 16 to 24 h) for expression of C-terminal Strep-
hemagglutinin (HA)-tagged RIG-I. Dengue virus serotype 2, strain 16681,
was cultivated on C6/36 cells, and titers were determined on BHK cells by
flow cytometry (54). Vesicular stomatitis virus expressing green fluores-
cent protein (VSV-GFP) was from the S. Whelan laboratory (Harvard
Medical School).
Plasmids and protein. The IFN--promoter-driven firefly luciferase
plasmid pIFN--luc was provided by J. Jung (University of Southern Cal-
ifornia). The constitutive thymidine-kinase-promoter-driven Renilla lu-
ciferase plasmid pTK-Renluc was provided by M. Gack (University of
Chicago). Human recombinant N-terminal 6 His-SUMO RIG-I was
expressed and purified as described previously (44).
RNA transcription. The poly U/UC sequence (6) was transcribed in
vitro from a short dsDNA template of annealed oligonucleotides from
IDT. Long (2.7-kb) dsRNA was derived from the VP2 gene of rotavirus, as
previously described (55). The sequence of interest was PCR amplified
with primers containing a SmaI linearization site and T7 promoter for
transcription, as well as KpnI and BamHI sites for cloning into the pUC19
plasmid. PolyI:C (GE Healthcare) was reconstituted in water.
Each RNA was transcribed in vitro using T7 Scribe (CellScript Inc.) or
Durascribe (Epicentre) kits, according to the manufacturer’s instructions.
Modified RNA was transcribed by 100% replacement with one of the follow-
ing modified NTPs: N6-methyladenosine (m6A), pseudouridine (), N1-
methylpseudouridine (m), 5-methylcytidine (5mC), 5-methoxycytidine
(5moC), 5-hydroxymethylcytidine (5hmC) (Trilink), 2= fluoro-deoxy-
uridine (2FdU), 2= fluoro-deoxycytidine (2FdC) (from the Durascribe kit
[Epicentre]). Radiolabeled RNA was transcribed in the presence of a 0.33
M final concentration of [-32P]CTP (EasyTides; PerkinElmer) and
2.5 mM nonradioactive CTP. The RNA concentration was determined by
the use of a NanoDrop 200 spectrophotometer (Thermo), and RNA pu-
rity was analyzed by capillary electrophoresis on a TapeStation 2200 in-
strument (Agilent).
Messenger RNAs (996 nt) encoding enhanced green fluorescent pro-
tein (EGFP) were provided by TriLink BioTechnologies, where they were
transcribed in vitrowith canonical nucleotides or complete substitution of
pseudouridine for uridine, followed by purification. Transcripts were
chemically modified with a CleanCap cotranscriptional capping system. A
liquid chromatography-mass spectrometry (LC-MS) capping assay re-
sulted in an estimation of 94% to 97% efficiency of generating
m7GpppNmpNpN (Cap-1) (data not shown). Capped mRNAs were
phosphatase treated to remove any residual 5= triphosphate termini.
Capped and uncapped (5= triphosphate-containing) control mRNAs were
HPLC purified (33).
Dual-luciferase assay. Huh7 cells were transfected in a 10-cm-
diameter dish at 90% confluence with reporter plasmids (5 g pIFN--
luc and 500 ng pTK-RenLuc) using LipoJet (SignaGen Laboratories) or
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s
protocol. The next morning, cells were released from the plate by mild
trypsin digestion and reseeded at 1 105 cells per well in a 24-well plate.
Triplicate wells were transfected with RNA (50 to 1,000 ng/well) that was
denatured at 85°C prior to complexing with LipoJet (SignaGen) or Lipo-
fectamine (Invitrogen) 2000. At 16 to 24 h posttransfection, cell lysate in a
96-well plate was analyzed in a TriStar LB491 (Berthold) plate reader with
automated injection of dual-luciferase reporter assay substrates (Pro-
mega). The fold induction of Firefly relative to Renilla was calculated per
well, averaged across triplicates, and normalized to mock-treated wells.
RIG-I induction of antiviral state.Huh7 cells were seeded in a 24-well
plate at 1 105 cells/well or in a 12-well plate at 2 105 cells/well. Cells
were transfected with 200 to 600 ng/well of the indicated RNA ligand
using Lipofectamine 2000 (Invitrogen) or LipoJet (SignaGen) or were
mock transfected (with transfection reagent with no RNA) or left un-
treated. At approximately 16 hpi, cells were infected with VSV-GFP or
mock infected in duplicate at a multiplicity of infection (MOI) of 3 or with
dengue virus (DenV) at a MOI of 1. At 6 hpi, VSV-GFP-infected cells were
imaged in an EVOS-fl microscope (Thermo Fisher). Then, VSV-GFP-
infected cells were scraped in cold phosphate-buffered saline (PBS) for
live-cell flow cytometry quantification of GFP cells. DenV-infected cells
were fixed at 36 to 48 hpi, permeabilized, and stained with anti-DenV NS1
antibody (Abcam clone DN2) and a fluorescein-conjugated secondary
antibody (Sigma). Flow cytometry was performed with a Guava flow cy-
tometer with EasyCyte software (EMD Millipore).
RIG-I:RNA filter binding assay. Filter binding reactions were per-
formed with 32P-radiolabeled RNA and recombinant purified RIG-I
passed through a nitrocellulose filter, with RNA detected by scintillation
counting. Data normalizations were performed as described previously
(56). See Text S1 in the supplemental material for details.
Biotinylated RNA pulldown. Confluent 10-cm-diameter dishes of
Huh7 cells were scraped in binding buffer (25 mM Tris-HCl [pH 7.5],
150 mM NaCl, 1.5 mM MgCl2) supplemented with 0.5% Triton X-100
and EDTA-free protease inhibitor (Roche). Binding reaction mixtures
contained 2 g of biotinylated RNA or nonbiotinylated RNA negative
control and 500 to 750 g of clarified lysate in a final volume of 120 l.
After 30 min, reaction mixtures were supplemented with 150 l of
streptavidin-conjugated paramagnetic bead slurry (Promega) and incu-
bated at room temperature for 1 h with rocking. Beads and associated
RNA:protein complexes were captured with a magnetic rack and washed
in binding buffer. Beads were boiled in SDS-PAGE sample buffer, and
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Western immunoblot analysis was performed using clone Alme-1 (Adi-
pogen) mouse anti-RIG-I antibody.
Limited trypsindigestion.Confluent 10-cm-diameter dishes of Huh7
or doxycycline-induced 293TdoxRIG-I cells were scraped in binding buf-
fer (25 mM Tris HCl [pH 7.5], 150 mM NaCl, 1.5 mM MgCl2) supple-
mented with 0.5% Triton X-100 without protease inhibitors. The concen-
tration of total protein in clarified lysates was determined by Bradford
assay. The reaction volume was 500 l and included 1 mg to 2 mg total
lysate protein, RNA (33 nM to 1 M), and 2 mM AMP-PNP (Roche) or
ATP (New England Biolabs). The reaction mixtures were incubated for
30 min at room temperature to permit RIG-I:RNA complex formation.
Next, tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated
trypsin (Sigma-Aldrich) was added to each reaction for a final mass ratio
of 1:400, and the reaction mixture was incubated at room temperature. At
the indicated time points (0 to 360 min), 25-l aliquots were removed for
boiling in SDS sample buffer. Experiments using multiple RNA concen-
trations were set up by serially diluting the RNA in binding buffer, with
digestions performed for 1.5 h with a 1:200 mass ratio of trypsin. RIG-I
fragments were visualized by immunoblotting using clone Alme-1 (Adi-
pogen) mouse anti-RIG-I helicase antibody or monoclonal mouse anti-
RIG-I CARDs (KeraFast).
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